In the presence of the Authorities of Zibo, represented by Mr. Zhuang Ming (Vice Mayor of Zibo City), and Mr. Zhang Daiming of Shandong Xinhua Pharmaceutical Cooperation Group, the groundbreaking ceremony for the construction of DSM Sinochem Pharmaceuticals’ newest production facility has taken place on December 9th, 2011 in Zibo’s High & New Technology Development Zone. The new plant will focus on the production and development of new Semi-Synthetic Cephalosporins (SSC) using proprietary biotechnology.
The facility will serve as a launch platform for new SSCs and facilitate pilot campaigns for new 2nd, 3rd and 4th generation SSCs. This investment allows DSM Sinochem Pharmaceuticals (DSP) to further drive its growth in China and fits well in the company strategy of strengthening the beta-lactam business and broadening DSP’s portfolio of Active Pharmaceutical Ingredients.
The new plant will use DSP’s proprietary enzymatic biotechnology. By using biotechnology DSP is able to reduce energy consumption by 66%, produce 90% less waste and have 50% less emissions to air, compared to the chemical process. This is a big step to make pharmaceutical products more environmentally sustainable.
The facility is planned to start operating in early 2013, to serve both the Chinese and the export market.
Hu Jian, Business Unit Director China for DSM Sinochem Pharmaceuticals, said: “This investment perfectly fits in our strategy to strengthen our current SSCs business and broaden our product portfolio. Exactly 2 years after we have opened a similar facility for the enzymatic production of 1st generation Cephalosporins here in Zibo, this is the natural next step in rolling out the advantages of our enzymatic production processes for pharmaceutical AIs to next generation products ”
DSM Sinochem Pharmaceuticals
DSM Sinochem Pharmaceuticals, established in Hong Kong, is a 50/50 Joint Venture of DSM, the global Life Science and Material Science Company, and Sinochem Group, a Fortune 500 enterprise. DSP develops, produces and sells raw materials, intermediates and active pharmaceutical ingredients (API) for anti-infectives such as antibiotics (for combating bacterial infections), anti-fungals (for combating fungal infections), and API for other therapeutic classes like cholesterol lowering medicines. Please visit www.dsm.com/dsp for more information
DSM Zibo is a joint venture between DSM Sinochem Pharmaceuticals and Shandong Xinhua Pharmaceutical Cooperation Group. It manufactures and markets the SSC range of Anti-Infectives.
